Unapproved retatrutide circulates online while Lilly trials continue
Flow Space reports dosing diaries and buying guides for a triple agonist that is not approved or commercially available anywhere in the world.
MH
By Maren Holt · Senior Reporter, GLP-1
Aug 6 03:00 ETSource: Flow Space
The wire
- 01Retatrutide, an investigational once-weekly GLP-1, GIP and glucagon receptor agonist from Eli Lilly, is being sold and discussed online despite having no FDA approval or commercial availability.
- 02Company-reported Phase 3 results cited in the piece show 28.3% average weight loss at 80 weeks on the highest dose in participants without diabetes, fueling gray-market demand clinicians are now fielding questions about.
- 03Material sold online is not verified as the trial compound; the 30.3% two-year figure comes from a subset extension study in participants with BMI of at least 35.
From the source
Read at theflowspace.comEveryone Wants ‘Reta.’ The Real Retatrutide Isn’t Even Available Yet.
By providing your information, you agree to our Terms of Use and our Privacy Policy . We use vendors that may also process your information to help provide our services.
